# To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)

> **NCT01072942** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Ciprofloxacin (Cipro InhaIe, BAYQ3939)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01072942
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072942, "To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01072942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*